Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $113,848.80 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider James William Burns sold 3,280 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $113,848.80. Following the completion of the sale, the insider directly owned 49,306 shares of the company’s stock, valued at approximately $1,711,411.26. This represents a 6.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Agios Pharmaceuticals Trading Down 1.1%

Shares of AGIO stock traded down $0.40 during trading hours on Monday, reaching $34.80. 1,068,723 shares of the company’s stock were exchanged, compared to its average volume of 933,677. Agios Pharmaceuticals, Inc. has a 1 year low of $22.24 and a 1 year high of $46.00. The stock has a market cap of $2.04 billion, a PE ratio of -4.89 and a beta of 0.79. The stock’s fifty day moving average price is $28.88 and its two-hundred day moving average price is $32.14.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Bank of America upped their price target on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 24th. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Friday, March 27th. Truist Financial boosted their price objective on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. JPMorgan Chase & Co. upped their target price on Agios Pharmaceuticals from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Monday. Finally, HC Wainwright raised their target price on Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $42.67.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of AGIO. Marshall Wace LLP increased its stake in shares of Agios Pharmaceuticals by 31.4% in the second quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company’s stock worth $22,772,000 after acquiring an additional 163,796 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Agios Pharmaceuticals during the third quarter worth $2,696,000. HighVista Strategies LLC lifted its position in Agios Pharmaceuticals by 178.5% during the third quarter. HighVista Strategies LLC now owns 195,298 shares of the biopharmaceutical company’s stock valued at $7,839,000 after purchasing an additional 125,171 shares during the period. Frazier Life Sciences Management L.P. boosted its holdings in Agios Pharmaceuticals by 19.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company’s stock valued at $42,565,000 after purchasing an additional 209,900 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its holdings in Agios Pharmaceuticals by 71.1% in the second quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company’s stock valued at $14,868,000 after purchasing an additional 185,798 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.